Biotechnology And Its Applications MCQs With Answers – Part 3 (Class 12 Biology)
GKaim: Measure | Improve | Achieve

Biotechnology and its Applications MCQs with Answers – Part 3 (Class 12 Biology)

Timer: Off
Random: Off

201. Why does the ability to genetically manipulate organisms create a need for ethical standards and regulation?
ⓐ. Genetic manipulation is biologically incapable of producing any benefit
ⓑ. Every genetically modified organism necessarily causes ecological damage
ⓒ. Biotechnology can provide benefits while also creating risks that require responsible evaluation
ⓓ. Regulation is needed only to control ordinary tissue culture
202. A genetically modified organism performs well under laboratory conditions, but researchers are uncertain how its release might affect non-target organisms and ecosystem interactions. The principal concern is:
ⓐ. ecological biosafety
ⓑ. C-peptide processing
ⓒ. recombinant insulin assembly
ⓓ. protoplast isolation
203. A proposed genetically modified crop passes tests for the intended trait, but a field study unexpectedly shows a harmful effect on a non-target organism. The most appropriate regulatory interpretation is that:
ⓐ. successful expression of the intended trait makes further assessment unnecessary
ⓑ. the unexpected effect is automatically a patent dispute
ⓒ. the crop should be treated as biologically identical to every conventional variety
ⓓ. the observation raises a biosafety concern that should be evaluated before wider release
204. In the historical context, the regulatory role attributed to GEAC is most closely associated with:
ⓐ. approving purification of a recombinant therapeutic for commercial production
ⓑ. overseeing routine tissue culture used for clonal plant propagation
ⓒ. assessing GM research validity and safety of proposed public use
ⓓ. deciding patent ownership for products based on traditional biological resources
205. A research group develops a genetically modified organism and proposes its use outside controlled laboratory conditions. According to the regulatory framework, the most relevant question for GEAC-type oversight is:
ⓐ. whether the organism contains an insulin A chain
ⓑ. whether research validity and public-use safety meet appropriate standards
ⓒ. whether the organism can undergo micropropagation
ⓓ. whether every gene in the organism has been sequenced
206. A company obtains legal protection over a biotechnology product or process involving a biological resource. This situation is most directly related to:
ⓐ. an ecological biosafety assessment of environmental release
ⓑ. an intellectual-property or patent matter
ⓒ. a benefit-sharing arrangement with biological-resource providers
ⓓ. an ethical assessment of how living organisms are used
207. The Basmati example is used primarily to illustrate a biotechnology-related dispute involving:
ⓐ. patent claims involving traditional Basmati germplasm and derived rice lines
ⓑ. biosafety testing of a GM rice line before environmental release
ⓒ. benefit sharing for authorised commercial use of rice germplasm
ⓓ. ecological effects of pest-resistant rice on non-target organisms
208. Consider the following historical reference facts about Basmati. I. India is described as having about \(200{,}000\) rice varieties. II. \(27\) documented Basmati varieties are mentioned. III. The Basmati patent dispute described is associated with \(1997\). IV. These figures should be treated as a complete current legal record of all rice-related patents. Which combination is valid?
ⓐ. I and IV only
ⓑ. II, III and IV only
ⓒ. I, III and IV only
ⓓ. I, II and III only
209. Turmeric and neem are mentioned alongside Basmati in discussions of biotechnology-related intellectual property because they illustrate:
ⓐ. examples of transgenic animals producing human proteins
ⓑ. disputes involving traditional biological knowledge or resources and patent claims
ⓒ. crops protected specifically by cryIAc
ⓓ. standard sources of recombinant human insulin
210. A company collects a medicinal plant used traditionally by an indigenous community, develops a profitable product from that knowledge, and proceeds without obtaining appropriate authorisation or sharing benefits with the community. This situation is best described as:
ⓐ. ordinary patent protection with no ethical dimension for the biological resource
ⓑ. ecological biosafety testing
ⓒ. biopiracy involving unauthorised exploitation without appropriate benefit sharing
ⓓ. gene therapy using a biological resource
Subscribe
Notify of
guest
0 Comments
Scroll to Top